Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 6/20 | 0.37 |
| ▸ | CTNNB1 | P35222 | 2/20 | 0.37 |
| ▸ | WNT3A | P56704 | 2/20 | 0.37 |
| ▸ | CLK1 | P49759 | 1/20 | 0.36 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.36 |
| ▸ | DYRK1B | Q9Y463 | 1/20 | 0.36 |
| ▸ | HTR1D | P28221 | 1/20 | 0.35 |
| ▸ | HTR2C | P28335 | 1/20 | 0.35 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL294882 | 0.88 | CHRM2 (0.40) | DYRK1ADYRK1B | |
| SCHEMBL648109 | 0.84 | DYRK1A (0.46) | CTNNB1WNT3ACLK1DYRK1ADYRK1B | |
| SCHEMBL97599 | 0.81 | — | — | |
| SCHEMBL12526764 | 0.78 | KCNH2 (0.38) | KCNH2CTNNB1WNT3ACLK1DYRK1A | |
| SCHEMBL8758775 | 0.78 | CTNNB1 (0.41) | KCNH2CTNNB1WNT3ACLK1DYRK1A | |
| SCHEMBL97600 | 0.77 | NPC1 (0.44) | — | |
| SCHEMBL3644639 | 0.76 | FABP6 (0.41) | KCNH2CTNNB1WNT3A | |
| SCHEMBL16596620 | 0.76 | KCNH2 (0.37) | KCNH2CTNNB1WNT3ACLK1DYRK1A | |
| SCHEMBL3524411 | 0.76 | LMNA (0.50) | KCNH2CTNNB1WNT3ACLK1DYRK1A | |
| SCHEMBL8699804 | 0.76 | MAOA (0.49) | CTNNB1WNT3A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7186734-B2 | Aryl imidazoles and related compounds as C5a receptor modulators | NEUROGEN CORPORATION (US) | 2007-03-06 | — | — | US | claimed |
| US-7169775-B2 | Amino methyl imidazoles as C5a receptor modulators | NEUROGEN CORPORATION (US) | 2007-01-30 | — | — | US | claimed |
| CN-1646497-A | Novel arylimidazoles and related compounds as modulators of the C5a receptor | NEUROGEN CORP (US) | 2005-07-27 | — | — | CN | claimed |
| EP-1490343-A1 | NEW ARYL IMIDAZOLES AND RELATED COMPOUNDS AS C5A RECEPTOR MODULATORS | Neurogen Corporation (US) | 2004-12-29 | — | — | EP | claimed |
| US-20040116424-A1 | Aryl imidazoles and related compounds as C5a receptor modulators | NEUROGEN CORPORATION | 2004-06-17 | — | — | US | claimed |
| US-20040082577-A1 | Amino methyl imidazoles as C5a receptor modulators | NEUROGEN CORPORATION | 2004-04-29 | — | — | US | claimed |
| WO-2004018460-A1 | AMINO METHYL IMIDAZOLES AS C5A RECEPTOR MODULATORS | NEUROGEN CORPORATION (US) | 2004-03-04 | — | — | WO | claimed |
| WO-2003082829-A1 | NEW ARYL IMIDAZOLES AND RELATED COMPOUNDS AS C5A RECEPTOR MODULATORS | NEUROGEN CORPORATION (US) | 2003-10-09 | — | — | WO | claimed |
| EP-4136084-A1 | BCL-2 INHIBITOR | BeiGene, Ltd. (KY) | 2023-02-22 | — | — | EP | disclosed |
| WO-2021208963-A1 | BCL-2 INHIBITOR | BEIGENE, LTD. (KY) | 2021-10-21 | — | — | WO | disclosed |
| US-8119665-B2 | Aryl imidazoles and related compounds as C5a receptor modulators | NOVARTIS INTERNATIONAL PHARMACEUTICAL LTD. (BM) | 2012-02-21 | — | — | US | disclosed |
| US-8007767-B2 | Amino methyl imidazoles and related compounds as C5a receptor modulators | NOVARTIS INTERNATIONAL PHARMACEUTICAL LTD. (BM) | 2011-08-30 | — | — | US | disclosed |
| EP-1490044-A4 | COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS | NEUROGEN CORP (US) | 2008-04-16 | — | — | EP | disclosed |
| US-20070212297-A1 | Amino methyl imidazoles and related compounds as C5a receptor modulators | NOVARTIS INTERNATIONAL PHARMACEUTICAL LTD. (BM) | 2007-09-13 | — | — | US | disclosed |
| US-20040116424-A1 | Aryl imidazoles and related compounds as C5a receptor modulators | NEUROGEN CORPORATION | 2004-06-17 | — | — | US | disclosed |
| US-20040082577-A1 | Amino methyl imidazoles as C5a receptor modulators | NEUROGEN CORPORATION | 2004-04-29 | — | — | US | disclosed |
| WO-2004018460-A1 | AMINO METHYL IMIDAZOLES AS C5A RECEPTOR MODULATORS | NEUROGEN CORPORATION (US) | 2004-03-04 | — | — | WO | disclosed |
| US-20040014782-A1 | Combination therapy for the treatment of diseases involving inflammatory components | NOVARTIS INTERNATIONAL PHARMACEUTICAL LTD. (BM) | 2004-01-22 | — | — | US | disclosed |
| WO-2003084524-A1 | COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS | NEUROGEN CORPORATION (US) | 2003-10-16 | — | — | WO | disclosed |
| WO-2003082829-A1 | NEW ARYL IMIDAZOLES AND RELATED COMPOUNDS AS C5A RECEPTOR MODULATORS | NEUROGEN CORPORATION (US) | 2003-10-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040082577-A1 | Amino methyl imidazoles as C5a receptor modulators | C5AR1, C5AR2, C3AR1 | KCNH2 1404/4885CTNNB1 4458/4885WNT3A 4039/4885 |
| US-20040014782-A1 | Combination therapy for the treatment of diseases involving inflammatory components | C5AR1, C5AR2, C3AR1 | KCNH2 3554/4885CTNNB1 3186/4885WNT3A 3250/4885 |
| US-20070212297-A1 | Amino methyl imidazoles and related compounds as C5a receptor modulators | C5AR1, C3AR1, C5AR2 | KCNH2 1442/4885CTNNB1 4469/4885WNT3A 3733/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.